Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (IPNSAE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03957616 |
Recruitment Status : Unknown
Verified May 2019 by Hospices Civils de Lyon.
Recruitment status was: Not yet recruiting
First Posted : May 21, 2019
Last Update Posted : May 21, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Paraneoplastic Neurological Syndrome Autoimmune Encephalitis |
Study Type : | Observational |
Estimated Enrollment : | 600 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018 |
Estimated Study Start Date : | May 30, 2019 |
Estimated Primary Completion Date : | May 30, 2019 |
Estimated Study Completion Date : | July 31, 2019 |

Group/Cohort |
---|
Paraneoplastic neurological syndromes patients
Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.
|
- Incidence and prevalence of diagnosed Paraneoplastic Neurological Syndromes (PNS) and Autoimmune Encephalitis (AE) between 2016 and 2018. [ Time Frame: 3 years ]Comparison between general population of the French counties and the cohort of PNS to calculate incidence and prevalence.
- Location (city) of diagnosis [ Time Frame: 1 hour ]Name of city where the diagnosis of Paraneoplastic Neurological Syndromes (PNS) or Autoimmune Encephalitis (AE) was made.
- French general population of each counties [ Time Frame: 3 years ]Person years for each region

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Clinical diagnosis of Paraneoplastic Neurological Syndrome (PNS) or Autoimmune Encephalitis (AE) made by the referring physician to the national center for PNS and AE in Lyon between 2016 and 2018
Exclusion Criteria:
- Data on location of diagnosis missing
- Patients diagnosed out of the mainland French territory
- Patients for whom insufficient data was available

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03957616
Contact: Géraldine Picard | 4 72 35 58 42 ext 33 | geraldine.picard@chu-lyon.fr | |
Contact: Jérôme Honnorat | 4 72 35 78 06 ext 33 | jerome.honnorat@chu-lyon.fr |
France | |
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes | |
Lyon, France, 69003 |
Principal Investigator: | Jérôme Honnorat | center for paraneoplastic neurological syndromes and autoimmune encephalitis |
Responsible Party: | Hospices Civils de Lyon |
ClinicalTrials.gov Identifier: | NCT03957616 |
Other Study ID Numbers: |
IPNSAE |
First Posted: | May 21, 2019 Key Record Dates |
Last Update Posted: | May 21, 2019 |
Last Verified: | May 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Encephalitis Hashimoto Disease Syndrome Disease Pathologic Processes Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Thyroiditis, Autoimmune Thyroiditis Thyroid Diseases Endocrine System Diseases |